OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Stephen A. Harrison, Sarah K. Browne, John J. Suschak, et al.
Journal of Hepatology (2024)
Open Access | Times Cited: 32
Stephen A. Harrison, Sarah K. Browne, John J. Suschak, et al.
Journal of Hepatology (2024)
Open Access | Times Cited: 32
Showing 1-25 of 32 citing articles:
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 19
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 19
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Children with Obesity: An Obesity Medicine Association (OMA) and Expert Joint Perspective 2025
Jennifer Panganiban, Mohit Kehar, Samar H. Ibrahim, et al.
Obesity Pillars (2025) Vol. 14, pp. 100164-100164
Open Access | Times Cited: 2
Jennifer Panganiban, Mohit Kehar, Samar H. Ibrahim, et al.
Obesity Pillars (2025) Vol. 14, pp. 100164-100164
Open Access | Times Cited: 2
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 9
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 9
Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics
Jinliang Liang, Huanyi Liu, Guo Lv, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Jinliang Liang, Huanyi Liu, Guo Lv, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
Jeysson E. Mejía-Guzmán, Ramón A. Belmont-Hernández, Norberto C. Chávez‐Tapia, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2959-2959
Open Access | Times Cited: 1
Jeysson E. Mejía-Guzmán, Ramón A. Belmont-Hernández, Norberto C. Chávez‐Tapia, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 2959-2959
Open Access | Times Cited: 1
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne, et al.
Gut (2024), pp. gutjnl-334023
Closed Access | Times Cited: 4
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne, et al.
Gut (2024), pp. gutjnl-334023
Closed Access | Times Cited: 4
Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease And Steatohepatitis: A Systematic Review and Network Meta-Analysis
Jie Li, Wenjing Ni, Xue Bai, et al.
(2025)
Closed Access
Jie Li, Wenjing Ni, Xue Bai, et al.
(2025)
Closed Access
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Wenjing Geng, Wanying Liao, Xinyuan Cao, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 393-393
Open Access
Wenjing Geng, Wanying Liao, Xinyuan Cao, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 393-393
Open Access
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
Role of anti-diabetic medications in the management of MASLD
Scott Isaacs, Fiona V Farrelly, Paul Brennan
Frontline Gastroenterology (2025), pp. flgastro-102856
Closed Access
Scott Isaacs, Fiona V Farrelly, Paul Brennan
Frontline Gastroenterology (2025), pp. flgastro-102856
Closed Access
Beyond Metabolic Benefits: The Underexplored Immunomodulatory Effects of GLP-1/Glucagon Agonists
Gustav van Niekerk, Johan Fevery, Kai Dallmeier
Journal of Hepatology (2025)
Closed Access
Gustav van Niekerk, Johan Fevery, Kai Dallmeier
Journal of Hepatology (2025)
Closed Access
Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga, et al.
Liver International (2025) Vol. 45, Iss. 5
Open Access
Oxyntomodulin-past, present and future
Jens J. Holst, Mette M. Rosenkilde
Peptides (2025), pp. 171393-171393
Closed Access
Jens J. Holst, Mette M. Rosenkilde
Peptides (2025), pp. 171393-171393
Closed Access
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Bryan Adrián Priego-Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access
Bryan Adrián Priego-Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access
Incretin-Based Therapies and Cancer: What’s New?
Sanja Medenica, Jelena Bogdanović, Jelena Vekić, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 678-678
Open Access
Sanja Medenica, Jelena Bogdanović, Jelena Vekić, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 678-678
Open Access
Antifibrotic Therapies for Metabolic Dysfunction-associated Steatotic Liver Disease
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, et al.
JHEP Reports (2025), pp. 101421-101421
Open Access
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, et al.
JHEP Reports (2025), pp. 101421-101421
Open Access
The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Kim Henriksen, Manu V. Chakravarthy, Cecilie Liv Bager, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Kim Henriksen, Manu V. Chakravarthy, Cecilie Liv Bager, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis
Qiao Ren, Yao Tan, Guixiang Zhang, et al.
Journal of Evidence-Based Medicine (2025) Vol. 18, Iss. 2
Closed Access
Qiao Ren, Yao Tan, Guixiang Zhang, et al.
Journal of Evidence-Based Medicine (2025) Vol. 18, Iss. 2
Closed Access
GLP-1-based therapies for diabetes, obesity and beyond
Daniel J. Drucker
Nature Reviews Drug Discovery (2025)
Closed Access
Daniel J. Drucker
Nature Reviews Drug Discovery (2025)
Closed Access
Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress
Erika Minetti, Naomi M. Hamburg, Reiko Matsui
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Erika Minetti, Naomi M. Hamburg, Reiko Matsui
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Drug treatment for MASLD: Progress and direction
Da Zhou, Jian‐Gao Fan
Chinese Medical Journal (2024)
Open Access | Times Cited: 3
Da Zhou, Jian‐Gao Fan
Chinese Medical Journal (2024)
Open Access | Times Cited: 3
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
Anmol Singh, Aalam Sohal, Akash Batta
World Journal of Gastroenterology (2024) Vol. 30, Iss. 48, pp. 5205-5211
Closed Access | Times Cited: 3
Anmol Singh, Aalam Sohal, Akash Batta
World Journal of Gastroenterology (2024) Vol. 30, Iss. 48, pp. 5205-5211
Closed Access | Times Cited: 3
Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types
Liu Liu, Muhammad Rashid, Jürgen Wess
Biochemistry (2025)
Closed Access
Liu Liu, Muhammad Rashid, Jürgen Wess
Biochemistry (2025)
Closed Access
Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group.
Luis Antonio Díaz, Juan Pablo Arab, Francisco Idalsoaga, et al.
Annals of Hepatology (2025), pp. 101903-101903
Open Access
Luis Antonio Díaz, Juan Pablo Arab, Francisco Idalsoaga, et al.
Annals of Hepatology (2025), pp. 101903-101903
Open Access
